Physician profile
Max M Haque
NPI 1700884111
$1,377.98
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $311 · 2021: $503 · 2022: $105 · 2023: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $249.98 | 2019-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.90 | 2021 | |
| Neurocrine Biosciences, INC. | $166.87 | 2019-2020 | |
| Abbvie INC. | $155.96 | 2021-2022 | |
| Lundbeck LLC | $125.23 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $95.45 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $75.51 | 2020-2022 | |
| Neuronetics, INC. | $63.76 | 2020 | |
| Alkermes, INC. | $48.30 | 2022 | |
| Allergan, INC. | $46.66 | 2019-2020 | |
| Neos Therapeutics, LP | $34.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.12 | 2019 | |
| Noven Pharmaceuticals, INC. | $22.40 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.54 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.28 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2019 | |
| Eisai INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.